Myocarditis and pericarditis following mRNA vaccination in autoimmune inflammatory rheumatic disease patients: A single‐center experience

作     者：Shreeya Patel Emma Wu Maninder Mundae Keith Lim Shreeya Patel;Emma Wu;Maninder Mundae;Keith Lim

作者机构：Department of RheumatologyWestern HospitalFootscrayVictoriaAustralia 

出 版 物：《Rheumatology & Autoimmunity》 (风湿病与自身免疫（英文）)

年 卷 期：2022年第2卷第2期

页      面：92-97页

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

主　　题：mRNA vaccines myocarditis pericarditis severe acute respiratory syndrome coronavirus 2(SARS‐CoV‐2) 

摘      要：Introduction:The mRNA vaccines Comirnaty(Pfizer/BioNTech)and Spikevax(Moderna)are considered safe and highly effective against SARS‐***,they are also associated with a small increased risk of pericarditis and *** is concern about an increased risk of these complications in patients with autoimmune inflammatory rheumatic diseases(AIRD).Case Report:We describe three patients with pre‐existing AIRD who developed myocarditis or pericarditis shortly after receiving their first dose of the Pfizer‐BioNTech *** first case is a 31‐year‐old female with systemic lupus erythematosus(SLE)and anti‐phospholipid syndrome(APLS)who presented 7 days after receiving the Pfizer‐BioNTech vaccine and was diagnosed with myopericarditis following a positive troponin and abnormal transthoracic echocardiogram(TTE).The second case is a 29‐year‐old man with seronegative inflammatory arthritis and APLS who presented 7 days after receiving the first dose of the Pfizer‐BioNTech *** troponin and TTE were unremarkable however his ECG showed widespread ST ***,the third case is a 34‐year‐old man with Behcet s disease with a history of recurrent *** developed a recurrence of symptoms approximately 7 days after his Pfizer‐BioNTech vaccine and self‐commenced prednisolone at *** had normal laboratory and radiological *** patients received prednisolone resulting in a quick recovery and resolution of ***:In this review we discuss the association between myocarditis,pericarditis and mRNA COVID‐19 vaccines,those who are at greatest risk and current clinical *** also discuss the possible increased risk in AIRD patients and the current research supporting this.